Atara Biotherapeutics, Inc. (ATRA)
9.76
+0.23
(+2.41%)
USD |
NASDAQ |
Sep 04, 16:00
10.34
+0.58
(+5.94%)
After-Hours: 20:00
Atara Biotherapeutics Enterprise Value : 133.71M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 133.71M |
| September 03, 2026 | 131.54M |
| September 02, 2026 | 130.69M |
| September 01, 2026 | 126.72M |
| August 31, 2026 | 125.59M |
| August 28, 2026 | 128.42M |
| August 27, 2026 | 128.89M |
| August 26, 2026 | 130.12M |
| August 25, 2026 | 134.46M |
| August 24, 2026 | 130.87M |
| August 21, 2026 | 133.14M |
| August 20, 2026 | 130.12M |
| August 19, 2026 | 132.20M |
| August 18, 2026 | 123.89M |
| August 17, 2026 | 120.49M |
| August 14, 2026 | 117.94M |
| August 13, 2026 | 121.90M |
| August 12, 2026 | 128.66M |
| August 11, 2026 | 125.96M |
| August 10, 2026 | 122.85M |
| August 07, 2026 | 121.34M |
| August 06, 2026 | 119.45M |
| August 05, 2026 | 122.19M |
| August 04, 2026 | 124.36M |
| August 03, 2026 | 122.28M |
| Date | Value |
|---|---|
| July 31, 2026 | 120.68M |
| July 30, 2026 | 118.69M |
| July 29, 2026 | 117.65M |
| July 28, 2026 | 115.29M |
| July 27, 2026 | 114.35M |
| July 24, 2026 | 116.14M |
| July 23, 2026 | 118.69M |
| July 22, 2026 | 118.27M |
| July 21, 2026 | 123.04M |
| July 20, 2026 | 119.83M |
| July 17, 2026 | 120.77M |
| July 16, 2026 | 123.89M |
| July 15, 2026 | 122.28M |
| July 14, 2026 | 117.47M |
| July 13, 2026 | 123.41M |
| July 10, 2026 | 133.71M |
| July 09, 2026 | 135.45M |
| July 08, 2026 | 132.67M |
| July 07, 2026 | 138.43M |
| July 06, 2026 | 144.28M |
| July 02, 2026 | 151.56M |
| July 01, 2026 | 148.91M |
| June 30, 2026 | 149.95M |
| June 29, 2026 | 138.28M |
| June 26, 2026 | 132.67M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.989B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.834M |
| Revenue (Quarterly) | 0.63M |
| Total Expenses (Quarterly) | 5.464M |
| EPS Diluted (Quarterly) | -0.3216 |
| Gross Profit Margin (Quarterly) | 69.68% |
| Profit Margin (Quarterly) | -767.3% |
| Earnings Yield | -14.33% |
| Normalized Earnings Yield | -12.73 |